Enjaymo Generic Name & Formulations
Treatment of hemolysis in adults with cold agglutinin disease (CAD).
Enjaymo Dosage and Administration
See full labeling. Give by IV infusion over 1–2hrs based on body weight; infuse over 2hrs for patients with cardiopulmonary disease. Administer 6500mg (for patients weighing 39–<75kg) or 7500mg (for patients weighing ≥75kg) once weekly for the 1st 2 weeks, then every 2 weeks thereafter. Monitor for at least 2hrs after initial infusion and for 1hr after subsequent infusions for any infusion and/or hypersensitivity reactions.
Enjaymo Boxed Warnings
Increased risk of serious infections (including encapsulated bacteria N. meningitides (any serogroup), S. pneumoniae, H. influenzae). Vaccinate or revaccinate against encapsulated bacteria at least 2 weeks prior to initiation according to current ACIP guidelines; if urgent treatment is indicated in an unvaccinated patient, give vaccine(s) as soon as possible. Active systemic infections: monitor closely for worsening infection. Consider interruption if undergoing treatment for serious infections. Chronic systemic infections (eg, HBV, HCV, or HIV): not studied. Discontinue and provide supportive measures if hypersensitivity reactions occur. Monitor for infusion-related reactions, recurrent hemolysis after treatment discontinuation. Potential risk for autoimmune diseases (eg, SLE); monitor. Pregnancy. Nursing mothers.
Enjaymo Adverse Reactions
Rhinitis, headache, hypertension, acrocyanosis, Raynaud’s phenomenon, UTI, respiratory tract infection, bacterial infection, dizziness, fatigue, peripheral edema, arthralgia, cough, hypertension, nausea.
Enjaymo Clinical Trials
Enjaymo Patient Counseling